Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3 Study of the Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy (ORION)

NCT06122662 is registered in ClinicalTrials.gov with Amylyx Pharmaceuticals Inc. as lead sponsor.

NCT NCT06122662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06122662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3 Study of the Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy (ORION)
Lead sponsor
Amylyx Pharmaceuticals Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
December 21, 2023
Completion date
October 21, 2025
Enrollment
139 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

atypical parkinsonism, neurodegenerative diseases, progressive supranuclear palsy, psp